Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06008938 · ClinicalTrials.gov registry record
An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B
A clinical trial of Hemophilia B, sponsored by CSL Behring.
- Recruiting
- Registry status
- 500
- Enrollment target
- 12
- Study locations
NCT06008938 is a study of Hemophilia B that is actively recruiting participants, run by CSL Behring. The registered enrollment target is 500 participants, above the 72-participant average among 20 other Hemophilia B trials with a reported enrollment target (594% higher). The trial reports 12 study locations across 2 states.
The verdict
NCT06008938, a study of Hemophilia B, is actively recruiting participants, sponsored by CSL Behring.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 12
- Study locations
Study Summary
This observational, post-authorization, long-term follow-up study aims to investigate the short and long-term effectiveness and safety of HEMGENIX in patients with hemophilia B. The study will also include a cohort of patients with hemophilia B treated with FIX prophylaxis to enable interpretation of relevant efficacy and safety findings of HEMGENIX.
Conditions Studied
Interventions
- GENETIC HEMGENIX
- BIOLOGICAL Factor IX (FIX)
Study Locations (12)
Other
- Medical University Vienna - Vienna
- Aarhus Universitetshospital - Århus N
- Centre Hospitalier Universitaire de Brest / CHU Morvan - Brest
- Centre Régional de Traitement de l'Hémophilie - Nantes
- CHU Nancy - Hôpital Brabois - Vandœuvre-lès-Nancy
- Klinik für Angiologie/ Hämostaseologie - Berlin
- University of Clinic Bonn - Bonn
- Klinikum der Johann-Wolfgang Goethe Universitaet - Frankfurt
- Hannover Medical School - Hanover
- Hospital Alvaro Cunqueiro Dr. Manuel Rodriquez-Lopez - Vigo
- University Hospital Bern Inselspital - Bern
New York
- American Thrombosis and Hemostasis Network - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2023-06-15 |
| Est. Completion | 2043-08-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06008938
The ClinicalTrials.gov registry entry for NCT06008938 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 72-participant average among 20 other Hemophilia B trials with a reported enrollment target (594% higher). The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hemophilia B appearing as the primary indexed condition, and to 2 interventions - of which HEMGENIX is the first listed.
NCT06008938 reports 12 study locations spanning 2 distinct geographic areas - top geographies include Other, New York.
Frequently Asked Questions
What is clinical trial NCT06008938 about?
NCT06008938 is a clinical study titled "An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B". This observational, post-authorization, long-term follow-up study aims to investigate the short and long-term effectiveness and safety of HEMGENIX in patients with hemophilia B. The study will also include a cohort of patients with hemophilia B treated with FIX prophylaxis to enable interpretation o...
What is the current status of trial NCT06008938?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2023-06-15. Estimated completion is 2043-08-01.
What conditions does trial NCT06008938 study?
This clinical trial studies the following conditions: Hemophilia B.
What interventions are being tested in trial NCT06008938?
The interventions under investigation include: HEMGENIX (GENETIC), Factor IX (FIX) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06008938?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06008938 being conducted?
This trial has 12 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemophilia B
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
RECRUITING · Phase 3
-
BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B
RECRUITING · Phase 1
-
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
RECRUITING · Phase 3
-
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
RECRUITING · Phase 3
-
Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
RECRUITING · Phase 3
-
A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.